342 related articles for article (PubMed ID: 20528121)
41. Dysregulation of blood lymphocyte subsets and natural killer cells in schistosomal liver cirrhosis and hepatocellular carcinoma.
Attallah AM; Tabll AA; El-Sadany M; Ibrahim TA; El-Dosoky I
Clin Exp Med; 2003 Nov; 3(3):181-5. PubMed ID: 14648234
[TBL] [Abstract][Full Text] [Related]
42. Tumor-host immune interactions and dendritic cell dysfunction.
Yang L; Carbone DP
Adv Cancer Res; 2004; 92():13-27. PubMed ID: 15530555
[TBL] [Abstract][Full Text] [Related]
43. Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies.
Atreya I; Neurath MF
Expert Rev Anticancer Ther; 2008 Apr; 8(4):561-72. PubMed ID: 18402523
[TBL] [Abstract][Full Text] [Related]
44. Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma.
Mukaida N; Nakamoto Y
World J Gastroenterol; 2018 May; 24(17):1839-1858. PubMed ID: 29740200
[TBL] [Abstract][Full Text] [Related]
45. Hepatocellular carcinoma (HCC): current and evolving therapies.
Gish RG; Baron A
IDrugs; 2008 Mar; 11(3):198-203. PubMed ID: 18311657
[TBL] [Abstract][Full Text] [Related]
46. Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients.
Cai L; Zhang Z; Zhou L; Wang H; Fu J; Zhang S; Shi M; Zhang H; Yang Y; Wu H; Tien P; Wang FS
Clin Immunol; 2008 Dec; 129(3):428-37. PubMed ID: 18824414
[TBL] [Abstract][Full Text] [Related]
47. Dendritic cell based immunotherapy--a promising therapeutic approach for endocrine malignancies.
Sbiera S; Wortmann S; Fassnacht M
Horm Metab Res; 2008 Feb; 40(2):89-98. PubMed ID: 18283626
[TBL] [Abstract][Full Text] [Related]
48. [Clinical effects of dendritic cells pulsed with autologous hepatoma cell lysates on the postoperative recurrence and metastasis of hepatocellular carcinoma].
Gao J; Chen M; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2005 Jun; 13(6):432-5. PubMed ID: 15975277
[TBL] [Abstract][Full Text] [Related]
49. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
50. [Immunotherapy for hepatocellular carcinoma using dendritic cells].
Homma S; Toda G; Ohno T
Nihon Rinsho; 2001 Oct; 59 Suppl 6():693-8. PubMed ID: 11762039
[No Abstract] [Full Text] [Related]
51. [Cancer immunotherapy. Importance of overcoming immune suppression].
Malvicini M; Puchulo G; Matar P; Mazzolini G
Medicina (B Aires); 2010; 70(6):565-70. PubMed ID: 21163748
[TBL] [Abstract][Full Text] [Related]
52. Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy.
Amedei A; Niccolai E; Prisco D
Hum Vaccin Immunother; 2014; 10(11):3354-68. PubMed ID: 25483688
[TBL] [Abstract][Full Text] [Related]
53. [Hepatocellular carcinoma - from immunobiology to immunotherapy].
Flecken T; Schmidt N; Spangenberg HC; Thimme R
Z Gastroenterol; 2012 Jan; 50(1):47-56. PubMed ID: 22222798
[TBL] [Abstract][Full Text] [Related]
54. New generation cancer therapy: right direction for sure with some uncertainty.
Ueno Y
Hepatol Int; 2019 Jan; 13(1):22-24. PubMed ID: 30406337
[No Abstract] [Full Text] [Related]
55. Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC.
Greten TF; Ormandy LA; Fikuart A; Höchst B; Henschen S; Hörning M; Manns MP; Korangy F
J Immunother; 2010; 33(2):211-8. PubMed ID: 20139774
[TBL] [Abstract][Full Text] [Related]
56. Application of cancer-testis antigens in immunotherapy of hepatocellular carcinoma.
Seifi-Alan M; Shamsi R; Ghafouri-Fard S
Immunotherapy; 2018 Apr; 10(5):411-421. PubMed ID: 29473472
[TBL] [Abstract][Full Text] [Related]
57. Challenges in cancer vaccine development for hepatocellular carcinoma.
Buonaguro L; Petrizzo A; Tagliamonte M; Tornesello ML; Buonaguro FM
J Hepatol; 2013 Oct; 59(4):897-903. PubMed ID: 23714157
[TBL] [Abstract][Full Text] [Related]
58. Role of Immunity in Pathogenesis and Treatment of Hepatocellular Carcinoma.
Schmidt N; Thimme R
Dig Dis; 2016; 34(4):429-37. PubMed ID: 27170398
[TBL] [Abstract][Full Text] [Related]
59. Liver immunotolerance and hepatocellular carcinoma: Patho-physiological mechanisms and therapeutic perspectives.
Roth GS; Decaens T
Eur J Cancer; 2017 Dec; 87():101-112. PubMed ID: 29145036
[TBL] [Abstract][Full Text] [Related]
60. Immunotherapy for hepatocellular carcinoma.
Li S; Yang F; Ren X
Drug Discov Ther; 2015 Oct; 9(5):363-71. PubMed ID: 26632545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
